MedTrace Logo

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

NCT05007613 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-01-01

No results posted yet for this study

Summary

To demonstrate that combination of cabozantinib and atezolizumab is safe and efficacious in patients with recurrent/metastatic esophageal squamous cell carcinoma.

Conditions

Interventions

DRUG

Cabozantinib 40 MG

Cabozantinib (Cabometyx) 40 MG PO QD

DRUG

Atezolizumab Injection

atezolizumab (Tecentriq) 1200mg IVF 30-60mins Q3W

Sponsors & Collaborators

  • Ipsen

    collaborator INDUSTRY

  • Roche Pharma AG

    collaborator INDUSTRY

  • National Taiwan University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-23
Primary Completion
2024-07-17
Completion
2024-12-01
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05007613 on ClinicalTrials.gov